Pharmaceutical composition containing pyridyl glycine compound

A technology of composition and base amino, which is applied in the field of stabilizing the compound or its salt, can solve the problems that there is no record, and there is no record of the preservation effect of the pharmaceutical composition, so as to achieve sufficient safety, improve the preservation effect, and excellent preservation effect Effect

Active Publication Date: 2020-06-02
SANTEN PHARMA CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, there is no description containing isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or its salt, and containing ethylenediamine tetraacetic acid or its salt of the pharmaceutical composition, in addition, for improving (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-yl) in the pharmaceutical composition There is no record about the stability of isopropyl sulfonyl)aminomethyl}pyridin-2-ylamino)acetate or its salts and the preservation efficacy of pharmaceutical compositions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing pyridyl glycine compound
  • Pharmaceutical composition containing pyridyl glycine compound
  • Pharmaceutical composition containing pyridyl glycine compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0066] Preparation examples and test results are shown below, but these preparation examples and test results are for better understanding of the present invention and do not limit the scope of the present invention.

[0067] Preparation example

[0068] Representative formulation examples using this compound are shown below. In addition, in the following formulation examples, the compounding quantity of each component is the content in 100 mL of compositions.

preparation example 1

[0070] Eye drops (in 100mL)

[0071]

preparation example 2

[0073] Eye drops (in 100mL)

[0074]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The object of the present invention is to provide: a pharmaceutical composition containing the compound, the compound in the pharmaceutical composition is stable, and the pharmaceutical composition has excellent preservation effect; The method of the stability and preservation potency of pharmaceutical composition. The pharmaceutical composition involved in the present invention contains (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate isopropyl or a salt thereof, and ethylenediaminetetraacetic acid or a salt thereof.

Description

technical field [0001] The present invention relates to a compound containing (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or its salt A pharmaceutical composition, and a method for stabilizing the compound or a salt thereof. Background technique [0002] (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate isopropyl is represented by the following formula (1) compound. [0003] [0004] Patent Document 1 and Patent Document 2 describe (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetic acid iso Pyridyl glycine compounds such as propyl ester, Patent Document 1 describes a preparation example containing concentrated glycerin and polysorbate 80 as eye drops of pyridyl glycine compounds. [0005] However, there is no description containing isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or its salt, and contain...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/444A61K9/08A61K47/04A61K47/12A61K47/18A61K47/22A61K47/32A61P9/12A61P27/02A61P27/06
CPCA61K47/12A61K47/22A61K31/444A61K9/0048A61K47/02A61K47/26A61K47/44A61K47/183A61P27/02A61P27/06A61P9/12Y02A50/30
Inventor 远藤洋子
Owner SANTEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap